Risk factors for type 1 diabetes recurrence in immunosuppressed recipients of simultaneous pancreas-kidney transplants

American Journal of Transplantation

Volumn 16, Issue 1, 2016, Pages 235-245

  Vendrame, F ^a   Hopfner, Y Y ^a   Diamantopoulos, S ^a   Virdi, S K ^a   Allende, G ^a   Snowhite, I V ^a   Reijonen, H K ^b   Chen, L ^a   Ruiz, P ^a   Ciancio, G ^a   Hutton, J C ^c   Messinger, S ^a   Burke, G W ^a   Pugliese, A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; HEMOGLOBIN A1C; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; UNCLASSIFIED DRUG; ZINC TRANSPORTER; ZINC TRANSPORTER 8; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALLELE; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENETIC RISK; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOCOMPROMIZED PATIENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY PANCREAS TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CHILD; DIABETES MELLITUS, TYPE 1; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECURRENCE; RISK FACTORS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 84956902751     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13426     Document Type: Article

References (44)

1. Pugliese A., The multiple origins of type 1 diabetes. Diabet Med 2013; 30: 135-146.
2. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase HP, et al., Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996; 9: 379-83.
3. Verge CF, Gianani R, Kawasaki E, et al., Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45: 926-933.
4. Krischer JP, Cuthbertson DD, Yu L, et al., Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 103-108.
5. Vehik K, Beam CA, Mahon JL, et al., Development of autoantibodies in the TrialNet Natural History Study. Diabetes Care 2011; 34: 1897-1901.
6. Sosenko JM, Skyler JS, Palmer JP, et al., A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care 2011; 34: 2435-2437.
7. Ziegler AG, Rewers M, Simell O, et al., Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473-2479.
8. White SA, Shaw JA, Sutherland DE., Pancreas transplantation. Lancet 2009; 373: 1808-1817.
9. Dean PG, Kudva YC, Larson TS, Kremers WK, Stegall MD., Posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant 2008; 8: 175-182.
10. Neidlinger N, Singh N, Klein C, et al., Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant 2010; 10: 398-406.
11. Vendrame F, Pileggi A, Laughlin E, et al., Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010; 59: 947-957.
12. Gruessner RW, Pugliese A, Reijonen HK, et al., Development of diabetes mellitus in living pancreas donors and recipients. Expert Rev Clin Immunol 2011; 7: 543-551.
13. Sutherland DE, Sibley R, Xu XZ, et al., Twin-to-twin pancreas transplantation: Reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians 1984; 97: 80-87.
14. Sibley RK, Sutherland DE, Goetz F, Michael AF., Recurrent diabetes mellitus in the pancreas iso- and allograft: a light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985; 53: 132-144.
15. Sutherland DE, Goetz FC, Sibley RK., Recurrence of disease in pancreas transplants. Diabetes 1989; 38(Suppl 1): 85-87.
16. Nakhleh RE, Gruessner RW, Swanson PE, et al., Pancreas transplant pathology: A morphologic, immunohistochemical, and electron microscopic comparison of allogeneic grafts with rejection, syngeneic grafts, and chronic pancreatitis. Am J Surg Pathol 1991; 15: 246-256.
17. Santamaria P, Nakhleh RE, Sutherland DE, Barbosa JJ., Characterization of T lymphocytes infiltrating human pancreas allograft affected by isletitis and recurrent diabetes. Diabetes 1992; 41: 53-61.
18. Bosi E, Bottazzo GF, Secchi A, et al., Islet cell autoimmunity in type I diabetic patients after HLA-mismatched pancreas transplantation. Diabetes 1989; 38(Suppl 1): 82-84.
19. Dieterle CD, Hierl FX, Gutt B, et al., Insulin and islet autoantibodies after pancreas transplantation. Transpl Int 2005; 18: 1361-1365.
20. Lohmann T, Klemm T, Geissler F, et al., Islet cell-specific autoantibodies as potential markers for recurrence of autoimmune type 1 diabetes after simultaneous pancreas-kidney transplantation. Transplant Proc 2002; 34: 2249-2250.
21. Sundkvist G, Tyden G, Karlsson FA, Bolinder J., Islet autoimmunity before and after pancreas transplantation in patients with type I diabetes mellitus [letter] [In Process Citation]. Diabetologia 1998; 41: 1532-1533.
22. Esmatjes E, Rodriguez-Villar C, Ricart MJ, et al., Recurrence of immunological markers for type 1 (insulin-dependent) diabetes mellitus in immunosuppressed patients after pancreas transplantation. Transplantation 1998; 66: 128-131.
23. Thivolet C, Abou-Amara S, Martin X, et al., Serological markers of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation. Transplantation 2000; 69: 99-103.
24. Petruzzo P, Andreelli F, McGregor B, et al., Evidence of recurrent type I diabetes following HLA-mismatched pancreas transplantation. Diabetes Metab 2000; 26: 215-218.
25. Braghi S, Bonifacio E, Secchi A, Di Carlo V, Pozza G, Bosi E,. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes 2000; 49: 218-224.
26. Ishida-Oku M, Iwase M, Sugitani A, et al., A case of recurrent type 1 diabetes mellitus with insulitis of transplanted pancreas in simultaneous pancreas-kidney transplantation from cardiac death donor. Diabetologia 2010; 53: 341-345.
27. Assalino M, Genevay M, Morel P, Demuylder-Mischler S, Toso C, Berney T., Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation in the absence of GAD and IA-2 autoantibodies. Am J Transplant 2012; 12: 492-495.
28. Occhipinti M, Lampasona V, Vistoli F, et al., Zinc transporter 8 autoantibodies increase the predictive value of islet autoantibodies for function loss of technically successful solitary pancreas transplant. Transplantation 2011; 92: 674-677.
29. Martins LS, Henriques AC, Fonseca IM, et al., Pancreatic autoantibodies after pancreas-kidney transplantation-do they matter? Clin Transplant 2014; 28: 462-469.
30. Chimienti F, Devergnas S, Pattou F, et al., In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J Cell Sci 2006; 119: 4199-4206.
31. Davidson HW, Wenzlau JM, O'Brien RM., Zinc transporter 8 (ZnT8) and beta cell function. Trends Endocrinol Metabol TEM 2014; 25: 415-424.
32. Wenzlau JM, Liu Y, Yu L, et al., A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 2008; 57: 2693-2697.
33. Noble JA, Erlich HA., Genetics of type 1 diabetes. Cold Spring Harb Perspect Med 2012; 2: a007732.
34. Sibley RK, Sutherland DE., Pancreas transplantation: An immunohistologic and histopathologic examination of 100 grafts. Am J Pathol 1987; 128: 151-170.
35. Tyden G, Reinholt FP, Sundkvist G, Bolinder J., Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996; 335: 860-863.
36. Monti P, Heninger AK, Bonifacio E., Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. Curr Diab Rep 2009; 9: 113-118.
37. Huurman VA, Hilbrands R, Pinkse GG, et al., Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One 2008; 3: e2435.
38. Burke GW, Ciancio G, Olson L, Roth D, Miller J., Ten-year survival after simultaneous pancreas/kidney transplantation with bladder drainage and tacrolimus-based immunosuppression. Transplant Proc 2001; 33: 1681-1683.
39. Burke GW, III., Kaufman, DB, Millis, JM, et al., Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: Three-year results. Transplantation 2004; 77: 1269-1275.
40. Ciancio G, Sageshima J, Chen L, et al., Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: Randomized, single-center trial at 10 years. Am J Transplant 2012; 12: 3363-3376.
41. Ringers J, van der Torren CR, van de Linde P, et al., Pretransplantation GAD-autoantibody status to guide prophylactic antibody induction therapy in simultaneous pancreas and kidney transplantation. Transplantation 2013; 96: 745-752.
42. Laughlin E, Burke G, Pugliese A, Falk B, Nepom GT., Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol 2008; 128: 23-30.
43. Wenzlau JM, Juhl K, Yu L, et al., The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007; 104: 17040-17045.
44. Wenzlau JM, Walter M, Gardner TJ, et al., Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab 2010; 95: 4712-4719.